Brainstorm Cell Therapeutics (BCLI) Reports Q2 Loss of $0.16/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall Street rallies as AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Wall Street rallies as AI optimism reignites and Treasury yields retreat
BrainStorm Announces Financial Results for the Second Quarter of 2018 and Provides a Corporate Update
July 23, 2018 8:00 AM EDTNEW YORK and PETACH TIKVAH, Israel, July 23, 2018 /PRNewswire/ --Â BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today financial results for the second quarter and six months ended June 30, 2018.
"We are pleased with our accomplishments in the second quarter of 2018. Â We continue to execute on the ongoing Phase... More
